Patents by Inventor Jiangguo Ying

Jiangguo Ying has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250084386
    Abstract: Provided is a method for large-scale production of lentivirus by using GMP-level serum-free suspension cells. Said method comprises the following steps: (a) providing a seed solution of packaged cells; (b) inoculating the seed solution in a first culture solution; (c) carrying out subculture of the packaged cells; (d) starting a liquid change operation when a liquid change trigger condition is met; (e) repeating steps (c) and (d) 1, 2 or 3 times; (f) starting a transfection operation when a transfection trigger condition is met; (g) optionally performing liquid change after transfection; (h) cultivating the 10 transfected packaged cells; (i) starting harvesting and liquid change operations when a liquid change trigger condition is met; (j) repeating steps (h) and (i) 1, 2 or 3 times; (k) combining each of the recovered liquids; and (1) performing a purifying treatment. The culture solution used in each step is a serum-free cell culture solution.
    Type: Application
    Filed: November 27, 2024
    Publication date: March 13, 2025
    Applicant: Shanghai Abelzeta Ltd.
    Inventors: Yi HONG, Ting YAN, Jiangguo YING, Haojie ZHANG, Luyi ZHANG, Li ZHANG
  • Patent number: 12180513
    Abstract: Provided is a method for large-scale production of lentivirus by using GMP-level serum-free suspension cells. Said method comprises the following steps: (a) providing a seed solution of packaged cells; (b) inoculating the seed solution in a first culture solution; (c) carrying out subculture of the packaged cells; (d) starting a liquid change operation when a liquid change trigger condition is met; (e) repeating steps (c) and (d) 1, 2 or 3 times; (f) starting a transfection operation when a transfection trigger condition is met; (g) optionally performing liquid change after transfection; (h) cultivating the transfected packaged cells; (i) starting harvesting and liquid change operations when a liquid change trigger condition is met; (j) repeating steps (h) and (i) 1, 2 or 3 times; (k) combining each of the recovered liquids; and (l) performing a purifying treatment. The culture solution used in each step is a serum-free cell culture solution.
    Type: Grant
    Filed: October 31, 2023
    Date of Patent: December 31, 2024
    Assignee: Shanghai AbelZeta Ltd.
    Inventors: Yi Hong, Ting Yan, Jiangguo Ying, Haojie Zhang, Luyi Zhang, Li Zhang
  • Publication number: 20240309337
    Abstract: Provided is a method for large-scale preparation of a purified preparation of a recombinant lentiviral vector at the GMP grade. The method comprises: (a) providing raw material feed liquid to be purified that comprises recombinant viral vectors; (b) carrying out a microfiltration treatment on the feed liquid to obtain a microfiltered filtrate comprising the recombinant viral vectors; (c) optionally concentrating the filtrate to obtain a concentrated filtrate; (d) purifying the filtrate obtained in the previous step by means of chromatography to obtain a crude pure product comprising the recombinant viral vectors; and (e) subjecting the crude pure product obtained in the previous step to liquid exchange and elaborate purification to obtain the purified recombinant viral vectors.
    Type: Application
    Filed: May 24, 2024
    Publication date: September 19, 2024
    Applicant: ABELZETA INC.
    Inventors: Yi HONG, Ting YAN, Jiangguo YING, Haojie ZHANG, Li ZHANG, Fei WANG, Dijun ZHAO, Luyi ZHANG
  • Patent number: 12018293
    Abstract: Provided is a method for large-scale preparation of a purified preparation of a recombinant lentiviral vector at the GMP grade. The method comprises: (a) providing raw material feed liquid to be purified that comprises recombinant viral vectors; (b) carrying out a microfiltration treatment on the feed liquid to obtain a microfiltered filtrate comprising the recombinant viral vectors; (c) optionally concentrating the filtrate to obtain a concentrated filtrate; (d) purifying the filtrate obtained in the previous step by means of chromatography to obtain a crude pure product comprising the recombinant viral vectors; and (e) subjecting the crude pure product obtained in the previous step to liquid exchange and elaborate purification to obtain the purified recombinant viral vectors.
    Type: Grant
    Filed: March 28, 2019
    Date of Patent: June 25, 2024
    Assignee: ABELZETA INC.
    Inventors: Yi Hong, Ting Yan, Jiangguo Ying, Haojie Zhang, Li Zhang, Fei Wang, Dijun Zhao, Luyi Zhang
  • Publication number: 20240060053
    Abstract: Provided is a method for large-scale production of lentivirus by using GMP-level serum-free suspension cells. Said method comprises the following steps: (a) providing a seed solution of packaged cells; (b) inoculating the seed solution in a first culture solution; (c) carrying out subculture of the packaged cells; (d) starting a liquid change operation when a liquid change trigger condition is met; (e) repeating steps (c) and (d) 1, 2 or 3 times; (f) starting a transfection operation when a transfection trigger condition is met; (g) optionally performing liquid change after transfection; (h) cultivating the transfected packaged cells; (i) starting harvesting and liquid change operations when a liquid change trigger condition is met; (j) repeating steps (h) and (i) 1, 2 or 3 times; (k) combining each of the recovered liquids; and (l) performing a purifying treatment. The culture solution used in each step is a serum-free cell culture solution.
    Type: Application
    Filed: October 31, 2023
    Publication date: February 22, 2024
    Applicant: Shanghai Cellular Biopharmaceutical Group Ltd.
    Inventors: Yi HONG, Ting YAN, Jiangguo YING, Haojie ZHANG, Luyi ZHANG, Li ZHANG
  • Patent number: 11845962
    Abstract: Provided is a method for large-scale production of lentivirus by using GMP-level serum-free suspension cells. Said method comprises the following steps: (a) providing a seed solution of packaged cells; (b) inoculating the seed solution in a first culture solution; (c) carrying out subculture of the packaged cells; (d) starting a liquid change operation when a liquid change trigger condition is met; (e) repeating steps (c) and (d) 1, 2 or 3 times; (f) starting a transfection operation when a transfection trigger condition is met; (g) optionally performing liquid change after transfection; (h) cultivating the transfected packaged cells; (i) starting harvesting and liquid change operations when a liquid change trigger condition is met; (j) repeating steps (h) and (i) 1, 2 or 3 times; (k) combining each of the recovered liquids; and (1) performing a purifying treatment. The culture solution used in each step is a serum-free cell culture solution.
    Type: Grant
    Filed: March 28, 2019
    Date of Patent: December 19, 2023
    Assignee: SHANGHAI CELLULAR BIOPHARMACEUTICAL GROUP LTD.
    Inventors: Yi Hong, Ting Yan, Jiangguo Ying, Haojie Zhang, Luyi Zhang, Li Zhang
  • Publication number: 20210363497
    Abstract: Provided is a method for large-scale production of lentivirus by using GMP-level serum-free suspension cells. Said method comprises the following steps: (a) providing a seed solution of packaged cells; (b) inoculating the seed solution in a first culture solution; (c) carrying out subculture of the packaged cells; (d) starting a liquid change operation when a liquid change trigger condition is met; (e) repeating steps (c) and (d) 1, 2 or 3 times; (f) starting a transfection operation when a transfection trigger condition is met; (g) optionally performing liquid change after transfection; (h) cultivating the transfected packaged cells; (i) starting harvesting and liquid change operations when a liquid change trigger condition is met; (j) repeating steps (h) and (i) 1, 2 or 3 times; (k) combining each of the recovered liquids; and (1) performing a purifying treatment. The culture solution used in each step is a serum-free cell culture solution.
    Type: Application
    Filed: March 28, 2019
    Publication date: November 25, 2021
    Inventors: Yi HONG, Ting YAN, Jiangguo YING, Haojie ZHANG, Luyi ZHANG, Li ZHANG
  • Publication number: 20210147826
    Abstract: Provided is a method for large-scale preparation of a purified preparation of a recombinant lentiviral vector at the GMP grade. The method comprises: (a) providing raw material feed liquid to be purified that comprises recombinant viral vectors; (b) carrying out a microfiltration treatment on the feed liquid to obtain a microfiltered filtrate comprising the recombinant viral vectors; (c) optionally concentrating the filtrate to obtain a concentrated filtrate; (d) purifying the filtrate obtained in the previous step by means of chromatography to obtain a crude pure product comprising the recombinant viral vectors; and (e) subjecting the crude pure product obtained in the previous step to liquid exchange and elaborate purification to obtain the purified recombinant viral vectors.
    Type: Application
    Filed: September 28, 2020
    Publication date: May 20, 2021
    Inventors: Yi HONG, Ting YAN, Jiangguo YING, Haojie ZHANG, Li ZHANG, Fei WANG, Dijun ZHAO, Luyi ZHANG
  • Publication number: 20210009966
    Abstract: Provided is a method for large-scale preparation of a purified preparation of a recombinant lentiviral vector at the GMP grade. The method comprises: (a) providing raw material feed liquid to be purified that comprises recombinant viral vectors; (b) carrying out a microfiltration treatment on the feed liquid to obtain a microfiltered filtrate comprising the recombinant viral vectors; (c) optionally concentrating the filtrate to obtain a concentrated filtrate; (d) purifying the filtrate obtained in the previous step by means of chromatography to obtain a crude pure product comprising the recombinant viral vectors; and (e) subjecting the crude pure product obtained in the previous step to liquid exchange and elaborate purification to obtain the purified recombinant viral vectors.
    Type: Application
    Filed: March 28, 2019
    Publication date: January 14, 2021
    Applicants: SHANGHAI CELLULAR BIOPHARMACEUTICAL GROUP LTD., WUXI CELLULAR BIOPHARMACEUTICAL GROUP LTD.
    Inventors: Yi Hong, Ting Yan, Jiangguo Ying, Haojie Zhang, Li Zhang, Fei Wang, Dijun Zhao, Luyi Zhang